(716) (105) (716) (105)
Total other
income, net 916 134 5,307 778
(Loss)/income
before
income tax
expense and
minority interests (1,378) (202) 11,367 1,666
Income tax expense (457) (67) -- (4) (457) (67)
(Loss)/income
before minority
interests (1,835) (269) 10,910 1,599
Minority interests,
net of tax 377 55 377 55
Net (loss)/income (1,458) (214) 11,287 1,654
Three Months Ended December 31, 2008
(unaudited), continued
Actual Actual Adjustment Adjusted Adjusted
GAAP GAAP Non-GAAP Non-GAAP
RMB US$ RMB RMB US$
Net (loss)/in
come per share:
Basic and diluted (0.01) (0.00) 0.08 0.01
Basic weighted
average number
of shares
outstanding 150,575,955 150,575,955 150,575,955 150,575,955
Effect of
dilutive
potential
shares -- -- 10,500 10,500
Diluted
weighted
average
number of
shares
outstanding 150,575,955 150,575,955 150,586,455 150,586,455
Net (loss)/in
come per ADS:
Basic and
diluted (0.07) (0.01) 0.52 0.08
Basic
weighted
average
number of
ADSs
outstanding 21,510,851 21,510,851 21,510,851 21,510,851
Effect of
dilutive
potential
ADSs -- -- 1,500 1,500
Diluted
weighted
average
nu
'/>"/>SOURCE 3SBio Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Related biology technology :1.
3SBio Inc. Receives Official Recognition as a High-Tech Enterprise2.
3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 20093.
3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer4.
3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference5.
3SBio Inc. Announces Third Quarter 2008 Results6.
3SBio Inc. Files for SFDA Approval of NuLeusin7.
3SBio Inc. Announces Preliminary Third Quarter 2008 Results8.
3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 20089.
3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO10.
3SBio Inc. to Present at the UBS Global Life Sciences Conference11.
3SBio Inc. Announces Results of Annual General Meeting